Prior to this, Neuberger Berman, a New York-based investment management firm slashed PharmEasy’s valuation by 21 per cent to 4.4 billion as of February 28
The multi-brand restaurant chain's standalone net profit in the first half of (April-September) FY'23 stood at Rs 27.67 crore from a turnover of Rs 195 crore, recovering from Covid pandemic headwinds
The filing offers OYO greater flexibility on the size of the issue during the initial stages of the process and allows the company to change the primary issue size by up to 50 per cent until the updated DRHP stage
The company reported an adjusted EBITDA of Rs 63 crore in the first half of FY2023 in its filing with Securities and Exchange Board of India (Sebi) in an update to its Draft Red Herring Prospectus (DRHP)